Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor 2 antagonist in painful knee osteoarthritis compared with MRI

Annals of the Rheumatic Diseases

Volumn 68, Issue 1, 2009, Pages 75-83

  Song, I H ^a   Althoff, C E ^a   Hermann, K G ^a   Scheel, A K ^b   Knetsch, T ^c   Burmester, G R ^a   Backhaus, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Department of Nephrology and Rheumatology ^*  (Germany)

^c Esaote   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ B2 RECEPTOR ANTAGONIST; ICATIBANT; PLACEBO;

ADULT; AGED; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B SCAN; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOPPLER ECHOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; KNEE OSTEOARTHRITIS; KNEE PAIN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; BRADYKININ; CONTRAST MEDIA; DOUBLE-BLIND METHOD; FEMALE; GADOLINIUM DTPA; HUMANS; KNEE JOINT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN; PHOSPHOLIPIDS; RECEPTOR, BRADYKININ B2; STATISTICS, NONPARAMETRIC; SULFUR HEXAFLUORIDE; TREATMENT OUTCOME;

EID: 58349102921     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2007.080382     Document Type: Article

References (66)

1. Ostergaard M, Court-Payen M, Gideon P, Wieslander S, Cortsen M, Lorenzen I, et al. Ultrasonography in arthritis of the knee. A comparison with MR imaging. Acta Radiol 1995; 36:19-26.
2. Hill CL, Gale DG, Chaisson CE, Skinner K, Kazis L, Gale ME, et al. Knee effusions, popliteal cysts, and synovial thickening: association with knee pain in osteoarthritis. J Rheumatol 2001; 28:1330-7.
3. Schmidt WA, Volker L, Zacher J, Schlafke M, Ruhnke M, Gromnica-lhle E. Colour Doppler ultrasonography to detect pannus in knee joint synovitis. Clin Exp Rheumatol 2000; 18:439-44.
4. Dieppe P, Cushnaghan J, Young P. Kirwan J. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis 1993; 52:557-63.
5. Dougados M, Gueguen A, Nguyen M, Thiesce A, Listrat V, Jacob L, et al. Longitudinal radiologic evaluation of osteoarthritis of the knee. J Rheumatol 1992; 19:378-84.
6. Ayral X, Ravaud P, Bonvarlet JP, Simonnet J, Lecurieux R, Nguyen M, et al. Arthroscopic evaluation of post-traumatic patellofemoral chondropathy. J Rheumatol 1999; 26:1140-7.
7. Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005; 64:1263-7.
8. Creamer P, Hunt M, Dieppe P. Pain mechanisms in osteoarthritis of the knee: effect of intraarticular anesthetic. J Rheumatol 1996; 23:1031-6.
9. Likar R, Schafer M, Paulak F, Sittl R, Pipam W, Schalk H, et al. Intraarticular morphine analgesia in chronic pain patients with osteoarthritis. Anesth Analg 1997; 84:1313-7.
10. Blais C Jr, Couture R, Drapeau G, Colman RW, Adam A. Involvement of endogenous kinins in the pathogenesis of peptidoglycan-induced arthritis in the Lewis rat. Arthritis Rheum 1997; 40:1327-33.
11. Tonussi CR, Ferreira SH. Bradykinin-induced knee joint incapacitation involves bradykinin B2 receptor mediated hyperalgesia and bradykinin B1 receptor-mediated nociception. Eur J Pharmacol 1997; 326:61-5.
12. Sharma JN, Wirth KJ. Inhibition of rats adjuvant arthritis by a bradykinin antagonist Hoe 140 and its influence on kallikreins. Gen Pharmacol 1996; 27:133-6.
13. Marceau F, Regoli D. Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 2004; 3:845-52.
14. Bathon JM, Proud D, Krackow K, Wigley FM. Preincubation of human synovial cells with IL-1 modulates prostaglandin E2 release in response to bradykinin. J Immunol 1989; 143:579-86.
15. Nishimura M, Segami N, Kaneyama K, Suzuki T, Miyamaru M. Relationships between pain-related mediators and both synovitis and joint pain in patients with internal derangements and osteoarthritis of the temporomandibular joint. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 94:328-32.
16. Flechtenmacher J, Talke M, Heil K, Veith D, Gebauer A, Schönharting M. Bradykininrezeptorhemmung - ein neuer Therapieansatz bei Arthroseschmerz. Orthopäd. Unfallchirur 2005:196.
17. Song IH, Althoff CE, Hermann KG, Scheel AK, Knetsch T, Schoenharting M, et al. Knee osteoarthritis. Efficacy of a new method of contrast-enhanced musculoskeletal ultrasonography in detection of synovitis in patients with knee osteoarthritis in comparison with magnetic resonance imaging. Ann Rheum Dis 2008: 67;19-25.
18. Salaffi F, Carotti M, Manganelli P, Filippucci E, Giuseppetti GM, Grassi W. Contrastenhanced power Doppler sonography of knee synovitis in rheumatoid arthritis: assessment of therapeutic response. Clin Rheumatol 2004; 23:285-90.
19. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16:494-502.
20. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29:1039-49.
21. Backhaus M, Burmester GR, Gerber T, Grassi W, Machold KP, Swen WA, et al. Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 2001; 60:641-9.
22. Bokor D. Diagnostic efficacy of SonoVue. Am J Cardiol 2000: 86:19G-24G.
23. Rizzatto G, Martegani A, Chersevani R, Macorig D, Vrtovec M, Aiani L, et al. Importance of staging of breast cancer and role of contrast ultrasound. Eur Radiol 2001; 11(Suppl 3):E47-51.
24. Lassau N, Koscielny S, Opolon P, De Baere T, Peronneau P, Leclere J, et al. Evaluation of contrast-enhanced color Doppler ultrasound for the quantification of angiogenesis in vivo. Invest Radiol 2001; 36:50-5.
25. Eshed I. Althoff CE, Schink T, Scheel AK, Schirmer C, Backhaus M, et al. Low-field MRI for assessing synovitis in patients with rheumatoid arthritis. Impact of Gd-DTPA dose on synovitis scoring. Scand J Rheumatol 2006; 35:277-82.
26. Hermann KG, Backhaus M, Schneider U, Labs K, Loreck D, Zuhlsdorf S, et al. Rheumatoid arthritis of the shoulder joint: comparison of conventional radiography, ultrasound, and dynamic contrast-enhanced magnetic resonance imaging. Arthritis Rheum 2003; 48:3338-49.
27. Morrison WB. Indirect MR arthrography: concepts and controversies. Semin Musculoskelet Radiol 2005; 9:125-34.
28. Jbara M, Chen O, Marten P, Morcos M, Beltran J. Shoulder MR arthrography: how, why, when. Radiol Clin North Am 2005; 43:683-92.
29. Diehr P, Psaty BM, Patrick DL. Effect size and power for clinical trials that measure years of healthy life. Stat Med 1997; 16:1211-23.
30. Thalheimer WCS. How to calculate effect sizes from published articles: a simplified methodology, http://work-learing.com/effect-sizes.htm (accessed 16 October 2007).
31. Adamietz B, Wenkel E, Uder M, Meyer T, Schneider I, Dimmler A, et al. Contrast enhanced sonography of the gallbladder: a tool in the diagnosis of cholecystitis? Eur J Radiol 2007; 61:262-6.
32. Lassau N, Lamuraglia M. Chami L, Leclere J, Bonvalot S. Terrier P, et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 2006; 187:1267-73.
33. Liu GJ, Xu HX, Lu MD, Xie XY, Xu ZF, Zheng YL, et al. Correlation between enhancement pattern of hepatocellular carcinoma on real-time contrast-enhanced ultrasound and tumour cellular differentiation on histopathology. Br J Radiol 2007: 80:321-30.
34. De Pascale A, Garofalo G, Perna M, Priola S, Fava C. Contrast-enhanced ultrasonography in Crohn's disease. Radiol Med (Torino) 2006; 111:539-50.
35. Zhou XD, Ren XL, Zhang J, He GB, Zheng MJ, Tian X, et al. Therapeutic response assessment of high intensity focused ultrasound therapy for uterine fibroid: utility of contrast-enhanced ultrasonography. Eur J Radiol 2007: 62:289-94.
36. Cassano E, Rizzo S, Bozzini A, Menna S, Bellomi M. Contrast enhanced ultrasound of breast cancer. Cancer Imaging 2006; 6:4-6.
37. Testa AC, Ferrandina G, Fruscella E, Van Holsbeke C, Ferrazzi E, Leone FP, et al. The use of contrasted transvaginal sonography in the diagnosis of gynecologic diseases: a preliminary study. J Ultrasound Med 2005; 24:1267-78.
38. Biagini E, van Geuns RJ, Baks T, Boersma E, Rizzello V, Galema TW, et al. Comparison between contrast echocardiography and magnetic resonance imaging to predict improvement of myocardial function after primary coronary intervention. Am J Cardiol 2006; 97:361-6.
39. Giuseppetti GM, Argalia G, Salera D, Ranald R, Danieli G. Cappelli M. Ultrasonographic contrast-enhanced study of sicca syndrome. Eur J Radiol 2005; 54:225-32.
40. Li R, Guo Y, Hua X, He Y, Ding J, Guo A, et al. Characterization of focal liver lesions: comparison of pulse-inversion harmonic contrast-enhanced sonography with contrast-enhanced CT. J Clin Ultrasound 2007; 35:109-17.
41. Doria AS, Kiss MH, Lotito AP, Molnar LJ, de Castro CC, Medeiros CC, et al. Juvenile rheumatoid arthritis of the knee: evaluation with contrast-enhanced color Doppler ultrasound. Pediatr Radiol 2001; 31:524-31.
42. Klauser A, Frauscher F, Schirmer M, Halpern E, Pallwein L, Herald M, et al. The value of contrast-enhanced color Doppler ultrasound in the detection of vascularization of finger joints in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46:647-53.
43. Magarelli N, Guglielmi G, Di Matteo L, Tartaro A, Mattei PA, Bonomo L. Diagnostic utility of an echo-contrast agent in patients with synovitis using power Doppler ultrasound: a preliminary study with comparison to contrast-enhanced MRI. Eur Radiol 2001; 11:1039-46.
44. Carotti M, Salaffi F, Manganelli P, Salera D, Simonetti B, Grassi W. Power Doppler sonography in the assessment of synovial tissue of the knee joint in rheumatoid arthritis: a preliminary experience. Ann Rheum Dis 2002; 61:877-82.
45. Fiocco U, Ferro F, Cozzi L, Vezzu M, Sfriso P, Checchetto C, et al. Contrast medium in power Doppler ultrasound for assessment of synovial vascularity: comparison with arthroscopy. J Rheumatol 2003; 30:2170-6.
46. Ovistgaard E, Rogind H, Torp-Pedersen S, Terslev L, Danneskiold-Samsoe B, Bliddal H. Quantitative ultrasonography in rheumatoid arthritis: evaluation of inflammation by Doppler technique. Ann Rheum Dis 2001; 60:690-3.
47. Szkudlarek M, Court-Payen M, Strandberg C, Klarlund M, Klausen T, Ostergaard M. Contrast-enhanced power Doppler ultrasonography of the metacarpophalangeal joints in rheumatoid arthritis. Eur Radiol 2003; 13:163-8.
48. Wamser G, Bohndorf K, Vollert K, Bucklein W, Schalm J. Power Doppler sonography with and without echo-enhancing contrast agent and contrast-enhanced MRI for the evaluation of rheumatoid arthritis of the shoulder joint: differentiation between synovitis and joint effusion. Skeletal Radiol 2003; 32:351-9.
49. Klauser A, Demharter J, De Marchi A, Sureda D, Barile A, Masciocchi C, et al. Contrast enhanced gray-scale sonography in assessment of joint vascularity in rheumatoid arthritis: results from the IACUS study group. Eur Radiol 2005; 15:2404-10.
50. Kleffel T, Demharter J, Wohlgemuth W, Schalm J, Bohndorf K, Kirchhof K. Comparison of contrast-enhanced low mechanical index (Low ML) sonography and unenhanced B-mode sonography for the differentiation between synovitis and joint effusion in patients with rheumatoid arthritis. Rofo 2005; 177:835-41.
51. Fiocco U, Ferro F, Vezzu M, Cozzi L, Checchetto C, Sfriso P, et al. Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power Doppler ultrasound assessment of the response to etanercept. Ann Rheum Dis 2005; 64:899-905.
52. Hau M, Kneitz C, Tony HP, Keberle M, Jahns R, Jenett M. High resolution ultrasound detects a decrease in pannus vascularisation of small finger joints in patients with rheumatoid arthritis receiving treatment with soluble tumour necrosis factor α receptor (etanercept). Ann Rheum Dis 2002; 61:55-8.
53. Terslev L, Torp-Pedersen S, Qvistgaard E, Kristoffersen H, Rogind H, Danneskiold-Samsoe B, et al. Effects of treatment with etanercept (Enbrel, TNRF:Fc) on rheumatoid arthritis evaluated by Doppler ultrasonography. Ann Rheum Dis 2003; 62:178-81.
54. Ribbens C, Andre B, Marcelis S, Kaye O, Mathy L, Bonnet V, et al. Rheumatoid hand joint synovitis: gray-scale and power Doppler US quantifications following anti-tumor necrosis factor-α treatment: pilot study. Radiology 2003; 229:562-9.
55. Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJ, Marsters PA, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 2004; 50:1107-16.
56. Rhaleb NE, Rouissi N, Jukic D, Regoli D, Henke S, Breipohl G, et al. Pharmacological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg- [Hyp3, Thi5, D-Tic7, Qic8]bradykinin). Eur J Pharmacol 1992; 210:115-20.
57. Bond AP, Breipohl G, Worthy K, Campion G, Dieppe PA, Bhoola KD. Metabolism and characterisation of kinins and Hoe 140 (kinin antagonist) in the synovial fluid of patients with inflammatory joint diseases. Agents Actions Suppl 1992; 38:582-9.
58. Regoli D, Nsa Allogho S, Rizzi A, Gobeil FJ. Bradykinin receptors and their antagonists. Eur J Pharmacol 1998; 348:1-10.
59. Perkins MN, Campbell E, Dray A. Antinociceptive activity of the bradykinin B1 and B2 receptor antagonists, des-Arg9, [Leu8]-BK and HOE 140, in two models of persistent hyperalgesia in the rat. Pain 1993; 53:191-7.
60. Davis AJ, Perkins MN. The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat. Br J Pharmacol 1994; 113:63-8.
61. Levy D, Zochodne DW. Increased mRNA expression of the B1 and B2 bradykinin receptors and antinociceptive effects of their antagonists in an animal model of neuropathic pain. Pain 2000; 86:265-71.
62. Damas J, Remacle-Volon G. Influence of a long-acting bradykinin antagonist, Hoe 140. on some acute inflammatory reactions in the rat. Eur J Pharmacol 1992; 211:81-6.
63. Biswal S, Medhi B, Pandhi P. Longterm efficacy of topical nonsteroidal antiinflammatory drugs in knee osteoarthritis: metaanalysis of randomized placebo controlled clinical trials. J Rheumatol 2006; 33:1841-4.
64. Bingham CO 3rd, Sebba Al, Rubin BR, Ruoff GE, Kremer J, Bird S, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 2007; 46:496-507.
65. Karlsson J, Sjogren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology (Oxford) 2002; 41:1240-8.
66. Pham T, Le Henanff A, Ravaud P, Dieppe P, Paolozzi L, Dougados M. Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis 2004; 63:1611-7.